f Commentary on the Role of Medicinal Cannabis in Healthy Aging and Neuroprotection

References

1. NagpalR. NethB.J. WangS. CraftS. YadavH. Modified Mediterranean-ketogenic diet modulates gut microbiome and short-chain fatty acids in association with Alzheimer’s disease markers in subjects with mild cognitive impairment.EBioMedicine20194752954210.1016/j.ebiom.2019.08.032 31477562
   [Google Scholar]
2. GaoL. LiuX. LuoX. LouX. LiP. LiX. LiuX. Antiaging effects of dietary supplements and natural products.Front. Pharmacol.202314119271410.3389/fphar.2023.1192714 37441528
   [Google Scholar]
3. WangZ. ArnoldJ.C. Cannabinoids and healthy ageing: The potential for extending healthspan and lifespan in preclinical models with an emphasis on Caenorhabditis elegans.Geroscience20244665643566110.1007/s11357‑024‑01162‑8 38696056
   [Google Scholar]
4. KaszyńskaA.A. Cannabinoids: Potential for modulation and enhancement when combined with vitamin B12 in case of neurodegenerative disorders.Pharmaceuticals202417681310.3390/ph17060813 38931480
   [Google Scholar]
5. Paes-ColliY. AguiarA.F.L. IsaacA.R. FerreiraB.K. CamposR.M.P. TrindadeP.M.P. de Melo ReisR.A. SampaioL.S. Phytocannabinoids and cannabis-based products as alternative pharmacotherapy in neurodegenerative diseases: From hypothesis to clinical practice.Front. Cell. Neurosci.20221691716410.3389/fncel.2022.917164 35707521
   [Google Scholar]
6. LiH. LiuY. TianD. TianL. JuX. QiL. WangY. LiangC. Overview of cannabidiol (CBD) and its analogues: Structures, biological activities, and neuroprotective mechanisms in epilepsy and Alzheimer’s disease.Eur. J. Med. Chem.202019211216310.1016/j.ejmech.2020.112163 32109623
   [Google Scholar]
7. BoniniS.A. PremoliM. TambaroS. KumarA. MaccarinelliG. MemoM. MastinuA. Cannabis sativa: A comprehensive ethnopharmacological review of a medicinal plant with a long history.J. Ethnopharmacol.201822730031510.1016/j.jep.2018.09.004 30205181
   [Google Scholar]
8. MessinaF. RosatiO. CuriniM. MarcotullioM.C. Cannabis and bioactive cannabinoids.Studies in Natural Products Chemistry.Elsevier2015175710.1016/B978‑0‑444‑63473‑3.00002‑2
   [Google Scholar]
9. KratzJ.W. García De PalauM. Handbook on medicinal cannabis.Kalapa Clinic2018
   [Google Scholar]
10. HanušL.O. MeyerS.M. MuñozE. Taglialatela-ScafatiO. AppendinoG. Phytocannabinoids: A unified critical inventory.Nat. Prod. Rep.201633121357139210.1039/C6NP00074F 27722705
    [Google Scholar]
11. MarzoratiS. FriscioneD. PicchiE. VerottaL. Cannabidiol from inflorescences of Cannabis sativa L.: Green extraction and purification processes.Ind. Crops Prod.202015511281610.1016/j.indcrop.2020.112816
    [Google Scholar]
12. RochfortS. IsbelA. EzernieksV. ElkinsA. VincentD. DeseoM.A. SpangenbergG.C. Utilisation of design of experiments approach to optimise supercritical fluid extraction of medicinal cannabis.Sci. Rep.2020101912410.1038/s41598‑020‑66119‑1 32499550
    [Google Scholar]
13. SunD. LiX. NieS. LiuJ. WangS. Disorders of cancer metabolism: The therapeutic potential of cannabinoids.Biomed. Pharmacother.202315711399310.1016/j.biopha.2022.113993 36379120
    [Google Scholar]
14. Aizpurua-OlaizolaO. ElezgaraiI. Rico-BarrioI. ZarandonaI. EtxebarriaN. UsobiagaA. Targeting the endocannabinoid system: Future therapeutic strategies.Drug Discov. Today201722110511010.1016/j.drudis.2016.08.005 27554802
    [Google Scholar]
15. BlebeaN.M. PricopieA.I. VladR.A. HancuG. Phytocannabinoids: Exploring pharmacological profiles and their impact on therapeutical use.Int. J. Mol. Sci.2024258420410.3390/ijms25084204 38673788
    [Google Scholar]
16. RezendeB. AlencarA.K.N. de BemG.F. Fontes-DantasF.L. MontesG.C. Endocannabinoid system: Chemical characteristics and biological activity.Pharmaceuticals202316214810.3390/ph16020148 37017445
    [Google Scholar]
17. Fernández-RuizJ. BerrenderoF. HernándezM.L. RamosJ.A. The endogenous cannabinoid system and brain development.Trends Neurosci.2000231142010.1016/S0166‑2236(99)01491‑5 10631784
    [Google Scholar]
18. ScotterE.L. AboodM.E. GlassM. The endocannabinoid system as a target for the treatment of neurodegenerative disease.Br. J. Pharmacol.2010160348049810.1111/j.1476‑5381.2010.00735.x 20590559
    [Google Scholar]
19. CristinoL. BisognoT. Di MarzoV. Cannabinoids and the expanded endocannabinoid system in neurological disorders.Nat. Rev. Neurol.202016192910.1038/s41582‑019‑0284‑z 31831863
    [Google Scholar]
20. Fernández-RuizJ. The biomedical challenge of neurodegenerative disorders: An opportunity for cannabinoid-based therapies to improve on the poor current therapeutic outcomes.Br. J. Pharmacol.2019176101370138310.1111/bph.14382 29856067
    [Google Scholar]
21. Ghasemi-GojaniE. KovalchukI. KovalchukO. Cannabinoids and terpenes for diabetes mellitus and its complications: From mechanisms to new therapies.Trends Endocrinol. Metab.2022331282884910.1016/j.tem.2022.08.003 36280497
    [Google Scholar]
22. Bilkei-GorzoA. The endocannabinoid system in normal and pathological brain ageing.Philos. Trans. R. Soc. Lond. B Biol. Sci.201236716073326334110.1098/rstb.2011.0388 23108550
    [Google Scholar]
23. HodgesE.L. AshpoleN.M. Aging circadian rhythms and cannabinoids.Neurobiol. Aging20197911011810.1016/j.neurobiolaging.2019.03.008 31035036
    [Google Scholar]
24. PiyanovaA. LomazzoE. BindilaL. LernerR. AlbayramO. RuhlT. LutzB. ZimmerA. Bilkei-GorzoA. Age-related changes in the endocannabinoid system in the mouse hippocampus.Mech. Ageing Dev.2015150556410.1016/j.mad.2015.08.005 26278494
    [Google Scholar]
25. Bilkei-GorzoA. RaczI. ValverdeO. OttoM. MichelK. SarstreM. ZimmerA. Early age-related cognitive impairment in mice lacking cannabinoid CB1 receptors.Proc. Natl. Acad. Sci. USA200510243156701567510.1073/pnas.0504640102 16221768
    [Google Scholar]
26. GarcíaS. Martín GiménezV.M. Mocayar MarónF.J. ReiterR.J. ManuchaW. Melatonin and cannabinoids: Mitochondrial-targeted molecules that may reduce inflammaging in neurodegenerative diseases.Histol. Histopathol.202035878980010.14670/HH‑18‑212 32154907
    [Google Scholar]
27. Bilkei-GorzoA. AlbayramO. DraffehnA. MichelK. PiyanovaA. OppenheimerH. Dvir-GinzbergM. RáczI. UlasT. ImbeaultS. BabI. SchultzeJ.L. ZimmerA. A chronic low dose of Δ9-tetrahydrocannabinol (THC) restores cognitive function in old mice.Nat. Med.201723678278710.1038/nm.4311 28481360
    [Google Scholar]
28. SarneY. ToledanoR. RachmanyL. SassonE. DoronR. Reversal of age-related cognitive impairments in mice by an extremely low dose of tetrahydrocannabinol.Neurobiol. Aging20186117718610.1016/j.neurobiolaging.2017.09.025 29107185
    [Google Scholar]
29. YooH.B. DiMuzioJ. FilbeyF.M. Interaction of cannabis use and aging: From molecule to mind.J. Dual Diagn.202016114017610.1080/15504263.2019.1665218 31570066
    [Google Scholar]
30. ShapiraG. Israel-ElgaliI. GradM. AvnatE. RachmanyL. SarneY. ShomronN. Hippocampal differential expression underlying the neuroprotective effect of delta-9-tetrahydrocannabinol microdose on old mice.Front. Neurosci.202317118293210.3389/fnins.2023.1182932 37534036
    [Google Scholar]
31. KochmanL.J. dos SantosA.A. FornalC.A. JacobsB.L. Despite strong behavioral disruption, Δ9-tetrahydrocannabinol does not affect cell proliferation in the adult mouse dentate gyrus.Brain Res.200611131869310.1016/j.brainres.2006.07.080 16930565
    [Google Scholar]
32. FanN. YangH. ZhangJ. ChenC. Reduced expression of glutamate receptors and phosphorylation of CREB are responsible for in vivo Δ9-THC exposure-impaired hippocampal synaptic plasticity.J. Neurochem.2010112369170210.1111/j.1471‑4159.2009.06489.x 19912468
    [Google Scholar]
33. NidadavoluP. Bilkei-GorzoA. KrämerM. SchürmannB. PalmisanoM. BeinsE.C. MadeaB. ZimmerA. Efficacy of Δ9-tetrahydrocannabinol (THC) alone or in combination with a 1:1 ratio of cannabidiol (CBD) in reversing the spatial learning deficits in old mice.Front. Aging Neurosci.20211371885010.3389/fnagi.2021.718850 34526890
    [Google Scholar]
34. WeinsteinG. SznitmanS.R. The implications of late-life cannabis use on brain health: A mapping review and implications for future research.Ageing Res. Rev.20205910104110104110.1016/j.arr.2020.101041 32109605
    [Google Scholar]
35. GruberS.A. SagarK.A. DahlgrenM.K. GonencA. SmithR.T. LambrosA.M. CabreraK.B. LukasS.E. The grass might be greener: Medical Marijuana patients exhibit altered brain activity and improved executive function after 3 months of treatment.Front. Pharmacol.2018898310.3389/fphar.2017.00983 29387010
    [Google Scholar]
36. McKetinR. ParasuP. CherbuinN. EramudugollaR. AnsteyK.J. A longitudinal examination of the relationship between cannabis use and cognitive function in mid-life adults.Drug Alcohol Depend.201616913414010.1016/j.drugalcdep.2016.10.022 27810656
    [Google Scholar]
37. AuerR. VittinghoffE. YaffeK. KünziA. KerteszS.G. LevineD.A. AlbaneseE. WhitmerR.A. JacobsD.R. Jr. Sidney, S.; Glymour, M.M.; Pletcher, M.J. Association between lifetime marijuana use and cognitive function in middle age.JAMA Intern. Med.2016176335236110.1001/jamainternmed.2015.7841 26831916
    [Google Scholar]